Cargando…

Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2

Newly emerging SARS-CoV-2 variants may escape monoclonal antibodies (mAbs) and antiviral drugs. By using live virus assays, we assessed the ex vivo inhibition of the B.1 wild-type (WT), delta and omicron BA.1 and BA.2 lineages by post-infusion sera from 40 individuals treated with bamlanivimab/etese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiaschi, Lia, Dragoni, Filippo, Schiaroli, Elisabetta, Bergna, Annalisa, Rossetti, Barbara, Giammarino, Federica, Biba, Camilla, Gidari, Anna, Lai, Alessia, Nencioni, Cesira, Francisci, Daniela, Zazzi, Maurizio, Vicenti, Ilaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321742/ https://www.ncbi.nlm.nih.gov/pubmed/35891355 http://dx.doi.org/10.3390/v14071374

Ejemplares similares

Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies
por: Dragoni, Filippo, et al.
Publicado: (2022)

Emergence of omicron variant's sublineages BA.4 and BA.5: risks assessment and possible countermeasures
por: Dhawan, Manish, et al.
Publicado: (2022)

Evasion of neutralising antibodies by omicron sublineage BA.2.75
por: Sheward, Daniel J, et al.
Publicado: (2022)

First sequenced cases of Omicron BA.2 sublineage in Ecuador
por: Andrade-Molina, D.A., et al.
Publicado: (2023)

The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5
por: Shuai, Huiping, et al.
Publicado: (2023)

Classification of Omicron BA.1, BA.1.1, and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data
por: Hirotsu, Yosuke, et al.
Publicado: (2022)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Viral load decrease in SARS‐CoV‐2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents
por: Valentina, Mazzotta, et al.
Publicado: (2022)

COVID-19 Pneumonia in Fully Vaccinated Adults during the Dominance of the Omicron Sublineages BA.1.1 and BA.2 in Mexico
por: Murillo-Zamora, Efrén, et al.
Publicado: (2022)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

Low neutralisation of the omicron BA.2 sublineage in boosted individuals who had breakthrough infections
por: Karaba, Andrew H, et al.
Publicado: (2022)

Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
por: Sheward, Daniel J, et al.
Publicado: (2022)

Seroepidemiology of SARS-CoV-2 Virus in Healthcare Workers before Circulation of the Omicron Sublineages BA.4/BA.5 in Vojvodina, Serbia
por: Ristić, Mioljub, et al.
Publicado: (2022)

SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
por: Focosi, Daniele, et al.
Publicado: (2023)

Introduction and Rapid Spread of SARS-CoV-2 Omicron Variant and Dynamics of BA.1 and BA.1.1 Sublineages, Finland, December 2021
por: Vauhkonen, Hanna, et al.
Publicado: (2022)

Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2023)

Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria
por: Schiaroli, Elisabetta, et al.
Publicado: (2022)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: Genomic surveillance in Japan from September 2021 to March 2022
por: Hirotsu, Yosuke, et al.
Publicado: (2022)

Delineating the Spread and Prevalence of SARS-CoV-2 Omicron Sublineages (BA.1–BA.5) and Deltacron Using Wastewater in the Western Cape, South Africa( )
por: Johnson, Rabia, et al.
Publicado: (2022)

SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy
por: Vicenti, Ilaria, et al.
Publicado: (2023)

Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75
por: Arora, Prerna, et al.
Publicado: (2022)

Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
por: Wang, Qian, et al.
Publicado: (2023)

Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals
por: Boccuto, Adele, et al.
Publicado: (2021)

Discrimination of SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 Using a High-Resolution Melting-Based Assay: a Pilot Study
por: Aoki, Akira, et al.
Publicado: (2022)

Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods
por: Link-Gelles, Ruth, et al.
Publicado: (2023)

Detection of a cluster of Omicron's BA.4 sublineage in Northern Senegal and identification of the first XAS recombinant variant in Senegal
por: Faye, Martin, et al.
Publicado: (2023)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies
por: Bruel, Timothée, et al.
Publicado: (2022)

Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected
por: Gidari, Anna, et al.
Publicado: (2021)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages
por: Guo, Li, et al.
Publicado: (2023)

Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai
por: Fu, Ziyu, et al.
Publicado: (2023)

The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
por: Arora, Prerna, et al.
Publicado: (2022)

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
por: Arora, Prerna, et al.
Publicado: (2023)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters
por: Su, Wen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sumbu3oa8smmkui8vncppivd2n